Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Organisation › Details

Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. *

 

Period Start 2001-01-01 established
  Group Ablynx (Group)
Products Industry BIOTECH
  Industry 2 Nanobodies®
Persons Person Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
  Person 2 Heylen, Johan (Ablynx 201411– CCO before GSK + Servier + Wyeth)
     
Region Region Zwijnaarde
  Country Belgium
  Street 21 Technologiepark
  City 9052 Zwijnaarde
  Tel +32-9-262-0000
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 85,187,000 (income, total (2016) 2016-12-31)
  Profit -1,087,000 (2016-12-31)
  Cash 208,600,000 (2017-09-30)
     
    * Document for �About Section�: Ablynx N.V.. (7/20/17). "Press Release: Ablynx and Sanofi Enter into a Strategic Collaboration to Develop Nanobody Product Candidates Focused on Immune-mediated Inflammatory Diseases". Ghent.
     
   
Record changed: 2018-10-30

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Ablynx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top